JP2009529367A - 銀結合抗菌性湿潤創傷被覆材を製造する方法及び該方法により製造された湿潤創傷被覆材 - Google Patents
銀結合抗菌性湿潤創傷被覆材を製造する方法及び該方法により製造された湿潤創傷被覆材 Download PDFInfo
- Publication number
- JP2009529367A JP2009529367A JP2008558209A JP2008558209A JP2009529367A JP 2009529367 A JP2009529367 A JP 2009529367A JP 2008558209 A JP2008558209 A JP 2008558209A JP 2008558209 A JP2008558209 A JP 2008558209A JP 2009529367 A JP2009529367 A JP 2009529367A
- Authority
- JP
- Japan
- Prior art keywords
- silver
- cmc
- compound
- wound dressing
- ion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 21
- 229910052709 silver Inorganic materials 0.000 claims abstract description 106
- 239000004332 silver Substances 0.000 claims abstract description 106
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 78
- 239000000243 solution Substances 0.000 claims abstract description 36
- -1 silver ions Chemical class 0.000 claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 32
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims abstract description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 239000003960 organic solvent Substances 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 94
- 239000010410 layer Substances 0.000 claims description 62
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 54
- 230000001681 protective effect Effects 0.000 claims description 19
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 17
- 230000000845 anti-microbial effect Effects 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims description 8
- 229920000742 Cotton Polymers 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 6
- 239000000017 hydrogel Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims description 4
- 229910001923 silver oxide Inorganic materials 0.000 claims description 4
- 229910021607 Silver chloride Inorganic materials 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 3
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 claims description 2
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 claims description 2
- RBWNDBNSJFCLBZ-UHFFFAOYSA-N 7-methyl-5,6,7,8-tetrahydro-3h-[1]benzothiolo[2,3-d]pyrimidine-4-thione Chemical compound N1=CNC(=S)C2=C1SC1=C2CCC(C)C1 RBWNDBNSJFCLBZ-UHFFFAOYSA-N 0.000 claims description 2
- 229910021612 Silver iodide Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940071536 silver acetate Drugs 0.000 claims description 2
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 claims description 2
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 claims description 2
- 229910001958 silver carbonate Inorganic materials 0.000 claims description 2
- 229940096017 silver fluoride Drugs 0.000 claims description 2
- 229940045105 silver iodide Drugs 0.000 claims description 2
- REYHXKZHIMGNSE-UHFFFAOYSA-M silver monofluoride Chemical compound [F-].[Ag+] REYHXKZHIMGNSE-UHFFFAOYSA-M 0.000 claims description 2
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 claims description 2
- 229940019931 silver phosphate Drugs 0.000 claims description 2
- 229910000161 silver phosphate Inorganic materials 0.000 claims description 2
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 claims description 2
- 229910000367 silver sulfate Inorganic materials 0.000 claims description 2
- RHUVFRWZKMEWNS-UHFFFAOYSA-M silver thiocyanate Chemical compound [Ag+].[S-]C#N RHUVFRWZKMEWNS-UHFFFAOYSA-M 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims 2
- 239000003513 alkali Substances 0.000 claims 1
- ONVGIJBNBDUBCM-UHFFFAOYSA-N silver;silver Chemical compound [Ag].[Ag+] ONVGIJBNBDUBCM-UHFFFAOYSA-N 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 109
- 208000027418 Wounds and injury Diseases 0.000 description 109
- 241000894006 Bacteria Species 0.000 description 13
- 210000000416 exudates and transudate Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000029663 wound healing Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 229940127554 medical product Drugs 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000513 bioprotective effect Effects 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
化合物を製造し、該銀−CMC化合物を媒体中へ分散しそして吸収させ、そして該媒体を乾燥する。
【選択図】図1
Description
本発明は、カルボキシメチルセルロースナトリウム(C6H9OCH2COONa、以後
CMCと略される)が化学的に銀に結合されている、抗菌活性を有する、抗菌性湿潤創傷被覆材(antimicrobial moist wound dressings)を製造する方法に関する。より具体的には、本発明は、CMCの水酸基の水素イオン(H+)を銀イオン(Ag+)と置換することにより(即ち、アルコキシレーションにより)製造された、銀−CMC化合物を用いて、種々の病原性細菌に起因する感染を治療及び予防するために用いられ得る、銀結合抗菌性湿潤創傷被覆材に関する。
、典型的な医療関連の製品は、急性の創傷、例えばやけど、及び慢性の創傷、例えば褥瘡性潰瘍、糖尿病による足の壊疽、の治療のための抗菌性創傷被覆材である。
は細胞中へ容易に浸透し、従って細胞に有害である。この場合において、生死にかかわる結果を引き起こすリスクが存在する。
技術的問題
創傷被覆材を製造する方法が提供される:
合し、それにより該CMCの水酸基の水素イオン(H+)を該銀イオンにより置換して、
銀−CMC化合物を製造する工程;
提供される。
(NH4)2CO3,NH4Cl及びKCNを含む。NH4OHが好ましく用いられる。水溶
液中の該アルカリ性溶媒の濃度は、好ましくは0.1%乃至30.0%の範囲である。該アルカリ性溶媒の濃度が0.1%より低いと、銀の再結晶化が妨害され得ない。その一方で、該アルカリ性溶媒の濃度が30%より高いと、銀イオンはもはや銀含有化合物から解離せず、これは経済的に不都合である。
た銀イオンの再結晶化を防止する役割を果たし、銀含有溶液をより均質にする。特に、該アルカリ性溶媒は以下に記載するように、CMCの水酸基の水素イオン(H+)と銀イオ
ンを置換する作用を果たす。
−CMC化合物が製造される。
覆材より溶解せず、そしてしたがって従来の創傷被覆材と異なり、正常細胞への損傷を防ぎ得る。
チルセルロースナトリウム:C6H9OCH2COONa)と結合させ、Ag+−CMC錯体をセルロースマトリックスへ導入し、そして、浸出が再水和により起こらないように、セルロースマトリックスを乾燥させることにより不可逆的にAg+−CMC錯体をセルロー
スマトリックスと結合させることを含む。CMCの水酸基の水素イオンが銀イオンにより置換される場合において、銀イオンは、水酸基へAgO又は酸化銀(AgO2 +)の形で、以下の一般式1に図示したように結合される。
であり得る。媒体として、純(100%)綿不織布又はガーゼが使用され得る。
その他の構成要素の層上に塗布され、全ての層は互いに付着し接合されることを意味し、そして単純な積層を含むことを意味する。
の水素イオンが銀イオンで置換されている化合物である。
Claims (15)
- 銀含有化合物をアルカリ性溶媒の0.1乃至30%の水溶液へ添加して該銀含有化合物から銀イオンを解離させる工程;
水又は有機溶媒中にカルボキシメチルセルロースナトリウム(C6H9CH2COONa,
CMC)を溶解してCMC溶液を得る工程;
該添加工程において得られる該銀イオン含有溶液を、該溶解工程において得られる該CMC溶液と混合し、それにより該CMCの水酸基の水素イオン(H+)を該銀イオンにより
置換して銀−CMC化合物を製造する工程;
媒体中に該銀−CMC化合物を分散しそして吸収する工程;そして
該媒体を乾燥する工程;
を含む、銀結合抗菌性湿潤創傷被覆材を製造する方法。 - 該銀含有化合物は、臭化銀、ヨウ化銀、フッ化銀及び塩化銀を含むハロゲン化銀、酢酸銀、炭酸銀、雷酸銀、硝酸銀、酸化銀、過塩素酸銀、リン酸銀、硫酸銀、チオシアン酸銀、及びこれらの混合物から選ばれる、請求項1に記載の方法。
- 該銀含有化合物が0.00001%乃至20.0%(w/v)の量で添加される、請求項1に記載の方法。
- 該アルカリ溶媒が、NaOH、Ca(OH)2,NH4OH、Na2S2O3、(NH4)2C
O3,NH4Cl、KCN、又はこれらの混合物である、請求項1に記載の方法。 - 該有機溶媒が、エタノール、イソプロピルアルコール、又はこれらの混合物である、請求項1に記載の方法。
- 該媒体が、純(100%)綿の不織布又はガーゼである、請求項1に記載の方法。
- 該乾燥が室温乃至200℃において行われる、請求項1に記載の方法。
- 銀含有化合物をアルカリ性溶媒の0.1乃至30%の水溶液へ添加して該銀含有化合物から銀イオンを解離させる工程;
水又は有機溶媒中にCMCを溶解してCMC溶液を得る工程;
該添加工程において得られる該銀イオン含有溶液を、該溶解工程において得られる該CMC溶液と混合し、それにより該CMCの水酸基の水素イオン(H+)を該銀イオンにより
置換して銀−CMC化合物を製造する工程;そして
該銀−CMC化合物を乾燥し、微粉化する工程;
を含む、銀結合抗菌性湿潤創傷被覆材を製造する方法。 - 互いに積層されそして接合された、皮膚と接触する感圧接着剤層、銀−CMC化合物が媒体中に分散する層(即ち、媒体層)、及び外部保護フィルム層を含む銀結合抗菌性保湿創傷被覆材であって、該銀−CMC化合物は、CMCの水酸基(OH-)の水素イオンを銀
イオンで置換することにより製造されるところの創傷被覆材。 - 該媒体層が、
銀含有化合物をアルカリ性溶媒の0.1乃至30%の水溶液へ添加して該銀含有化合物から銀イオンを解離させる工程;
水又は有機溶媒中にCMCを溶解してCMC溶液を得る工程;
該銀イオン含有溶液を、該CMC溶液と混合し、それにより該CMCの水酸基の水素イオン(H+)を該銀イオンにより置換して銀−CMC化合物を製造する工程;
媒体中に該銀−CMC化合物を分散しそして吸収する工程;そして
該媒体を乾燥する工程;
を含む方法により形成される、請求項9に記載の創傷被覆材。 - 該媒体が、純(100%)綿の不織布又はガーゼである、請求項10に記載の方法。
- 該外部保護フィルム層が、該媒体層より大きいサイズであり、そして該感圧接着剤層は、感圧接着剤を皮膚と接触する表面へ適用することにより形成される、請求項9に記載の創傷被覆材。
- 互いに積層されそして接合された、皮膚と接触する感圧接着剤層、銀−CMC粉末含有層、及び外部保護フィルム層を含む銀結合抗菌性保湿創傷被覆材であって、該銀−CMC粉末は、CMCの水酸基(OH-)の水素イオンが銀イオンにより置換された化合物を乾燥
し、次いで微粉化することにより、製造されるところの創傷被覆材。 - 該銀−CMC粉末含有層が、
銀含有化合物をアルカリ性溶媒の0.1乃至30%の水溶液へ添加して該銀含有化合物から銀イオンを解離させる工程;
水又は有機溶媒中にCMCを溶解してCMC溶液を得る工程;
該銀イオン含有溶液を、該CMC溶液と混合し、それにより該CMCの水酸基の水素イオン(H+)を該銀イオンにより置換して銀−CMC化合物を製造する工程;そして
該銀−CMC化合物を乾燥し微粉化する工程;
を含む方法により形成される、請求項13に記載の創傷被覆材。 - 該銀−CMC粉末含有層は、ハイドロゲル又はハイドロポリマータイプである、請求項13に記載の創傷被覆材。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2006-0022818 | 2006-03-10 | ||
KR1020060022818A KR100788997B1 (ko) | 2006-03-10 | 2006-03-10 | 은이 화학 결합된 항균성 습윤 드레싱재 제조방법 및 그습윤 드레싱재 |
PCT/KR2007/001173 WO2007105883A1 (en) | 2006-03-10 | 2007-03-09 | Methods for producing silver-bonded antimicrobial moist wound dressings and moist wound dressings produced by the methods |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009529367A true JP2009529367A (ja) | 2009-08-20 |
JP4984266B2 JP4984266B2 (ja) | 2012-07-25 |
Family
ID=38509674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008558209A Expired - Fee Related JP4984266B2 (ja) | 2006-03-10 | 2007-03-09 | 銀結合抗菌性湿潤創傷被覆材を製造する方法及び該方法により製造された湿潤創傷被覆材 |
Country Status (13)
Country | Link |
---|---|
US (2) | US8263116B2 (ja) |
EP (1) | EP1993620B1 (ja) |
JP (1) | JP4984266B2 (ja) |
KR (1) | KR100788997B1 (ja) |
CN (1) | CN101400379A (ja) |
AU (1) | AU2007225574B2 (ja) |
BR (1) | BRPI0708769A2 (ja) |
CA (1) | CA2644896C (ja) |
DK (1) | DK1993620T3 (ja) |
ES (1) | ES2441266T3 (ja) |
MX (1) | MX2008011571A (ja) |
RU (1) | RU2391116C1 (ja) |
WO (1) | WO2007105883A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180034499A (ko) * | 2015-07-24 | 2018-04-04 | 묄른뤼케 헬스 케어 에이비 | 흡수성 항균 상처 드레싱 |
JP2019508139A (ja) * | 2016-03-01 | 2019-03-28 | ケーシーアイ ライセンシング インコーポレイテッド | 医療用治療システムと共に使用されるドレープ |
JP2019514461A (ja) * | 2016-04-06 | 2019-06-06 | ウーペーエム−キュンメネ コーポレイションUPM−Kymmene Corporation | ナノフィブリルセルロースを含む医療用製品の製造方法、および医療用製品 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010207899B2 (en) * | 2009-01-28 | 2014-10-02 | Rau-Be Beteiligungen Gmbh | Wound cleansing assembly |
MX2012011452A (es) * | 2010-04-14 | 2012-11-23 | Moelnlycke Heatlh Care Ab | Geles antimicrobianos. |
CN101905031B (zh) * | 2010-07-16 | 2013-01-30 | 北京科技大学 | 一种磺胺嘧啶银/细菌纤维素复合伤口敷料的制备方法 |
RU2568909C2 (ru) * | 2011-08-12 | 2015-11-20 | Вячеслав Федорович Солтаганов | Повязка медицинская, способ ее изготовления и применения |
GB201209745D0 (en) * | 2012-05-31 | 2012-07-18 | Convatec Technologies Inc | Wound dressing |
US9119971B2 (en) * | 2012-07-26 | 2015-09-01 | Zoll Medical Corporation | Automated external defibrillator configuration |
CN103623453B (zh) * | 2013-12-06 | 2015-11-04 | 长春吉原生物科技有限公司 | 一种银离子水凝胶敷料的制备方法 |
CN104399106A (zh) * | 2014-12-02 | 2015-03-11 | 张凤 | 一种具有抗菌消炎作用的可溶性纤维及其制备方法 |
RU2728417C2 (ru) * | 2015-11-20 | 2020-07-29 | Эссити Хайджин Энд Хелт Актиеболаг | Волокнистая структура с противомикробным действием |
DE202016002788U1 (de) | 2016-04-28 | 2016-06-16 | Lohmann & Rauscher Gmbh | Applikationshilfe für die Behandlung von Wunden |
RU2659267C1 (ru) * | 2017-08-24 | 2018-06-29 | Федеральное государственное бюджетное учреждение науки Институт химии твердого тела Уральского отделения Российской академии наук | Способ получения серебросодержащей ткани растительного происхождения |
US10463760B2 (en) | 2017-10-31 | 2019-11-05 | InMEDBio, LLC | Absorbent, breathable and pathogen blocking/killing wound care dressing and fabrication thereof |
KR102040850B1 (ko) | 2017-11-02 | 2019-11-05 | 경기대학교 산학협력단 | 의료용 하이드로 콜로이드 조성물 및 이를 포함하는 의료용 드레싱 |
KR102117643B1 (ko) * | 2018-07-26 | 2020-06-03 | 주식회사 바이오팜메드 | 표면 키토산화 키틴 나노화이버 제조방법, 이로부터 제조된 표면 키토산화 키틴 나노화이버, 이를 이용한 키틴/콜라겐 나노화이버 원단 및 그 원단을 이용한 창상피복재 |
CN109260503A (zh) * | 2018-09-30 | 2019-01-25 | 振德医疗用品股份有限公司 | 一种吸收材料及其制备方法、包含该材料的敷料 |
CN112451738B (zh) * | 2020-11-30 | 2021-12-28 | 西安交通大学 | 一种银离子多糖聚合物抗菌敷料及其制备方法和应用 |
GB2609041A (en) * | 2021-07-20 | 2023-01-25 | Cellucomp Ltd | Water absorbing and antimicrobial fabric composition |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03242145A (ja) * | 1990-02-19 | 1991-10-29 | Terumo Corp | 創傷被覆材およびその製造方法 |
JPH07444A (ja) * | 1993-03-22 | 1995-01-06 | Bristol Myers Squibb Co | 創傷用包帯 |
JPH08113507A (ja) * | 1994-10-18 | 1996-05-07 | Rengo Co Ltd | 抗菌剤 |
JP2004508895A (ja) * | 2000-09-21 | 2004-03-25 | アコーディス スペシャリティー ファイバーズ リミティド | 創傷被覆材 |
JP2004520096A (ja) * | 2000-11-13 | 2004-07-08 | ジョンソン・アンド・ジョンソン・メディカル・リミテッド | ヒドロゲル創傷被覆材 |
JP2005501982A (ja) * | 2001-09-12 | 2005-01-20 | アコーディス スペシャリティー ファイバーズ リミティド | 抗細菌性創傷ドレッシング |
JP2005510296A (ja) * | 2001-11-23 | 2005-04-21 | ジョンソン・アンド・ジョンソン・メディカル・リミテッド | ヒドロゲル層を含む吸収性創傷被覆材 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1326416C (en) * | 1986-08-25 | 1994-01-25 | Ralph Xavier Ewall | Polymeric wound dressings |
DK158336C (da) | 1987-09-22 | 1990-10-01 | Coloplast As | Forbindsmateriale til behandling af saar samt smaalegemer til brug ved fremstilling deraf |
US6087549A (en) | 1997-09-22 | 2000-07-11 | Argentum International | Multilayer laminate wound dressing |
GB9717357D0 (en) * | 1997-08-16 | 1997-10-22 | Bristol Myers Squibb Co | Multi layered wound dressing |
US6605751B1 (en) | 1997-11-14 | 2003-08-12 | Acrymed | Silver-containing compositions, devices and methods for making |
US6719987B2 (en) | 2000-04-17 | 2004-04-13 | Nucryst Pharmaceuticals Corp. | Antimicrobial bioabsorbable materials |
US6379712B1 (en) * | 2000-09-13 | 2002-04-30 | Globoasia, L.L.C. | Nanosilver-containing antibacterial and antifungal granules and methods for preparing and using the same |
AU1993702A (en) | 2000-11-29 | 2002-06-11 | Bristol Myers Squibb Co | Light stabilized antimicrobial materials |
CA2495541C (en) | 2002-09-11 | 2011-07-12 | Johnson & Johnson Medical Limited | Wound dressing materials comprising complexes of anionic polysaccharides with silver |
KR100459494B1 (ko) | 2002-12-12 | 2004-12-03 | 한국원자력연구소 | 상처 치료용 수화겔의 제조방법 |
US20070089846A1 (en) * | 2004-01-30 | 2007-04-26 | Kim Ju Y | Silver-impregnated lignocellulose (sil): process for making and using same |
-
2006
- 2006-03-10 KR KR1020060022818A patent/KR100788997B1/ko not_active IP Right Cessation
-
2007
- 2007-03-09 MX MX2008011571A patent/MX2008011571A/es active IP Right Grant
- 2007-03-09 CA CA2644896A patent/CA2644896C/en not_active Expired - Fee Related
- 2007-03-09 WO PCT/KR2007/001173 patent/WO2007105883A1/en active Application Filing
- 2007-03-09 US US12/282,344 patent/US8263116B2/en not_active Expired - Fee Related
- 2007-03-09 CN CNA2007800085474A patent/CN101400379A/zh active Pending
- 2007-03-09 BR BRPI0708769-1A patent/BRPI0708769A2/pt not_active IP Right Cessation
- 2007-03-09 DK DK07715569.5T patent/DK1993620T3/da active
- 2007-03-09 JP JP2008558209A patent/JP4984266B2/ja not_active Expired - Fee Related
- 2007-03-09 ES ES07715569.5T patent/ES2441266T3/es active Active
- 2007-03-09 AU AU2007225574A patent/AU2007225574B2/en not_active Ceased
- 2007-03-09 EP EP07715569.5A patent/EP1993620B1/en active Active
- 2007-03-09 RU RU2008140174/15A patent/RU2391116C1/ru not_active IP Right Cessation
-
2012
- 2012-09-07 US US13/607,401 patent/US8409608B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03242145A (ja) * | 1990-02-19 | 1991-10-29 | Terumo Corp | 創傷被覆材およびその製造方法 |
JPH07444A (ja) * | 1993-03-22 | 1995-01-06 | Bristol Myers Squibb Co | 創傷用包帯 |
JPH08113507A (ja) * | 1994-10-18 | 1996-05-07 | Rengo Co Ltd | 抗菌剤 |
JP2004508895A (ja) * | 2000-09-21 | 2004-03-25 | アコーディス スペシャリティー ファイバーズ リミティド | 創傷被覆材 |
JP2004520096A (ja) * | 2000-11-13 | 2004-07-08 | ジョンソン・アンド・ジョンソン・メディカル・リミテッド | ヒドロゲル創傷被覆材 |
JP2005501982A (ja) * | 2001-09-12 | 2005-01-20 | アコーディス スペシャリティー ファイバーズ リミティド | 抗細菌性創傷ドレッシング |
JP2005510296A (ja) * | 2001-11-23 | 2005-04-21 | ジョンソン・アンド・ジョンソン・メディカル・リミテッド | ヒドロゲル層を含む吸収性創傷被覆材 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180034499A (ko) * | 2015-07-24 | 2018-04-04 | 묄른뤼케 헬스 케어 에이비 | 흡수성 항균 상처 드레싱 |
JP2018524121A (ja) * | 2015-07-24 | 2018-08-30 | メンリッケ・ヘルス・ケア・アーベー | 吸収性抗菌創傷ドレッシング |
KR102575066B1 (ko) * | 2015-07-24 | 2023-09-04 | 묄른뤼케 헬스 케어 에이비 | 흡수성 항균 상처 드레싱 |
JP2019508139A (ja) * | 2016-03-01 | 2019-03-28 | ケーシーアイ ライセンシング インコーポレイテッド | 医療用治療システムと共に使用されるドレープ |
JP6995765B2 (ja) | 2016-03-01 | 2022-01-17 | スリーエム イノベイティブ プロパティズ カンパニー | 医療用治療システムと共に使用されるドレープ |
JP2019514461A (ja) * | 2016-04-06 | 2019-06-06 | ウーペーエム−キュンメネ コーポレイションUPM−Kymmene Corporation | ナノフィブリルセルロースを含む医療用製品の製造方法、および医療用製品 |
JP7071281B2 (ja) | 2016-04-06 | 2022-05-18 | ウーペーエム-キュンメネ コーポレイション | ナノフィブリルセルロースを含む医療用製品の製造方法、および医療用製品 |
Also Published As
Publication number | Publication date |
---|---|
MX2008011571A (es) | 2008-09-22 |
AU2007225574A1 (en) | 2007-09-20 |
DK1993620T3 (da) | 2014-01-20 |
EP1993620A4 (en) | 2012-08-15 |
WO2007105883A1 (en) | 2007-09-20 |
US8409608B2 (en) | 2013-04-02 |
US8263116B2 (en) | 2012-09-11 |
CA2644896C (en) | 2013-01-08 |
RU2391116C1 (ru) | 2010-06-10 |
CN101400379A (zh) | 2009-04-01 |
JP4984266B2 (ja) | 2012-07-25 |
KR100788997B1 (ko) | 2007-12-28 |
ES2441266T3 (es) | 2014-02-03 |
CA2644896A1 (en) | 2007-09-20 |
EP1993620B1 (en) | 2013-10-09 |
US20090047332A1 (en) | 2009-02-19 |
AU2007225574B2 (en) | 2010-12-23 |
EP1993620A1 (en) | 2008-11-26 |
RU2008140174A (ru) | 2010-04-20 |
US20130006161A1 (en) | 2013-01-03 |
KR20070092537A (ko) | 2007-09-13 |
BRPI0708769A2 (pt) | 2011-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4984266B2 (ja) | 銀結合抗菌性湿潤創傷被覆材を製造する方法及び該方法により製造された湿潤創傷被覆材 | |
KR101377569B1 (ko) | 항균성 창상 피복재 및 그 제조방법 | |
JP4339592B2 (ja) | 抗微生物性銀化合物を含む医療用包帯 | |
EP1159972B1 (en) | Anti-microbial dressing using metallic compounds | |
WO2003009810A2 (en) | Silver alginate foam compositions | |
PL207044B1 (pl) | Materiał opatrunkowy na rany zawierający kompleks utlenionej celulozy ze srebrem, opatrunek zawierający ten materiał, oraz zastosowanie kompleksu do wytwarzania materiału opatrunkowego | |
JP6290184B2 (ja) | 創傷ドレッシング | |
JP4808402B2 (ja) | 陰イオン多糖と銀の複合体を含む創傷包帯材料 | |
Han | Interactive wound dressings | |
KR101366417B1 (ko) | 천연물질을 이용한 항균성 창상 피복재 및 그 제조방법 | |
US20080228123A1 (en) | Bandage with a hydrophilic foam containing silver and a hemastatic agent | |
CN114343975A (zh) | 一种创面湿性敷料及其制备方法 | |
EP2367575B1 (en) | Composition and dressing with nitric oxide | |
CN112957520B (zh) | 一种可见光催化抗菌水凝胶敷料及其制备方法 | |
CN111821504A (zh) | 一种银离子消毒凝胶及其制备方法 | |
CN118846182A (zh) | 用于伤口敷料的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090529 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120321 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120412 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |